Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Aura Biosciences, Inc.NASDAQ: AURA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$33.69M, compared with -$27.48M a year earlier. Trailing-twelve-month net income was -$112.39M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$95.96M (+9.6%) for the fiscal year ending Dec 2026, a step up from the -22.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$33.69M-31.8% QoQ
- Last fiscal yearDec 2025
- -$106.19M-22.2% YoY
- LTMMar 2026
- -$112.39M-18.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -22.6% | +6.4% | +29.0 pp |
| 1 year | -22.2% | +9.6% | +31.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (106.19M) USD
- Year-over-year change
- -22.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (106.19M) | -22.2% |
| FY2024 | 2024-12-31 | (86.92M) | -13.8% |
| FY2023 | 2023-12-31 | (76.41M) | -30.0% |
| FY2022 | 2022-12-31 | (58.76M) | -66.7% |
| FY2021 | 2021-12-31 | (35.25M) | — |
Net Income vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -18.7% is the 3rd highest of 11, against a peer median of -35.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$60.96M USD | -388.6% | — | 18297.5% | |
| FY2025 | -$63.73M USD | -44.9% | — | 980.9% | |
| LTM Mar 2026 | -$70.36M USD | -26.1% | — | 44.8% | |
| LTM Mar 2026 | -$71.67M USD | -24.7% | — | 1605.2% | |
| LTM Mar 2026 | -$84.53M USD | -68.1% | — | — | |
| LTM Mar 2026 | -CHF 95.06M CHF | +7.6% | — | 18861.3% | |
| LTM Mar 2026 | -$112.39M USD | -18.7% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.81M USD | -519.4% | — | — |
| LTM Mar 2026 | -$219.03M USD | -7.8% | — | 345.0% | |
| LTM Mar 2026 | -$271.6M USD | -85.0% | — | 3566.6% | |
| LTM Sep 2026 | -$282.65M USD | -26.9% | — | — | |
| Peer median (excluding AURA) | — | -35.9% | — | 1605.2% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.3M | 0 | 0 |
| Gross Profit | 0 | 0 | (1.3M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.16M | 42.24M | 63.94M | 73.3M | 90.3M |
| Selling, General & Admin | 10.09M | 18.06M | 19.76M | 22.81M | 22.49M |
| Operating Expenses | 35.25M | 60.3M | 83.7M | 96.12M | 112.79M |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| EBITDA | (34.41M) | (57.59M) | (74.98M) | (85.58M) | (104.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.25M) | (60.3M) | (84.99M) | (96.12M) | (112.79M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 1.86M | 8.59M | 9.43M | 6.63M |
| Interest Expense | 13K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1K) | 1.53M | 8.72M | 9.31M | 6.71M |
| Income Before Tax | (35.25M) | (58.76M) | (76.27M) | (86.81M) | (106.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 137K | 112K | 108K |
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| EPS (Diluted) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| Weighted Avg Shares | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
| Weighted Avg Shares (Diluted) | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.